172 related articles for article (PubMed ID: 32871512)
21. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
Wood CH; Robertson NP; Htet ZM; Tallantyre EC
Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
[TBL] [Abstract][Full Text] [Related]
22. Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
Purchiaroni F; Salvetti M; Buscarinu MC; Annibale B
Neurology; 2016 Aug; 87(9):952-3. PubMed ID: 27466473
[No Abstract] [Full Text] [Related]
23. Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T
Ann Neurol; 2022 May; 91(5):676-681. PubMed ID: 35170072
[TBL] [Abstract][Full Text] [Related]
24. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
Greenstein JI
Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
[TBL] [Abstract][Full Text] [Related]
25. Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
Bernardini LR; Zecca C; Clerici VT; Gobbi C; Mantegazza R; Rossi S
J Neurol Sci; 2016 Oct; 369():139-140. PubMed ID: 27653880
[No Abstract] [Full Text] [Related]
26. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
[TBL] [Abstract][Full Text] [Related]
27. Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera).
Di Bona D; Albanesi M; Giliberti LA; Nico A; Rossi MP; Caiaffa MF; Macchia L
J Allergy Clin Immunol Pract; 2017; 5(3):821-822. PubMed ID: 27888036
[No Abstract] [Full Text] [Related]
28. Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report.
Ciurleo R; Sessa E; Marino S; D'Aleo G; Bramanti P; Rifici C
Medicine (Baltimore); 2019 Apr; 98(17):e15185. PubMed ID: 31027063
[TBL] [Abstract][Full Text] [Related]
29. Listeria monocytogenes-Induced Rhombencephalitis in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate.
Ruggieri S; Logoteta A; Martini G; Bozzao A; De Giglio L
JAMA Neurol; 2018 Jun; 75(6):762-763. PubMed ID: 29610843
[No Abstract] [Full Text] [Related]
30. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
Popova EV; Boyko AN; Orlova EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
[TBL] [Abstract][Full Text] [Related]
31. Dimethyl fumarate-associated transient bone marrow oedema syndrome.
Triplett J; Vijayan S; Prince R; Kermode A
Mult Scler; 2019 May; 25(6):876-879. PubMed ID: 30051766
[TBL] [Abstract][Full Text] [Related]
32. Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate.
Jožef M; Locatelli I; Brecl Jakob G; Kos M; Rot U
Curr Med Res Opin; 2023 Nov; 39(11):1489-1496. PubMed ID: 37772491
[TBL] [Abstract][Full Text] [Related]
33. Delayed hypersensitivity to dimethyl fumarate: Report of 1 case and literature review.
Baglivo I; Colantuono S; Caruso C; De Fino C; Gasbarrini A; Capone M; D'Amore A; Peris K; Romano A; Parronchi P
J Allergy Clin Immunol Pract; 2023 May; 11(5):1562-1563.e2. PubMed ID: 36706983
[No Abstract] [Full Text] [Related]
34. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
[TBL] [Abstract][Full Text] [Related]
35. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Blair HA
Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
[TBL] [Abstract][Full Text] [Related]
36. Dimethyl fumarate induced migrating polyarthralgias.
Villedon de Naide M; Moisset X; Soubrier M
Joint Bone Spine; 2019 May; 86(3):399-400. PubMed ID: 30081200
[No Abstract] [Full Text] [Related]
37. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
38. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R
BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Zagmutt FJ; Carroll CA
Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
[TBL] [Abstract][Full Text] [Related]
40. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
